The Zacks Consensus Estimate for Merck’s Pharmaceutical unit is $14.96 billion, while our estimate is $14.8 billion. In the ...

driven by higher demand and pricing for companion animals and livestock products. That was partly offset by the impact of the ...

Merck Animal Health, a division of Merck & Co., Inc., Rahway, New Jersey, has introduced SENSEHUB Dairy Youngstock, the industry’s first monitoring technology for dairy calves from birth ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Zoetis' Livestock segment offers products for reproductive diseases in ... vaccine development and manufacturing capabilities. Merck & Co., Inc. (US) Merck & Co., Inc. is a global healthcare ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Merck MRK will report its third-quarter earnings on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.54 billion and $1.54 per share, respectively.